At the European Lung Cancer Conference last week in Geneva, Biodesix presented data from a multi-center Phase III study that showed VeriStrat was able to identify NSCLC patients most likely to have a "significant survival benefit" from treatment with Tarceva.
Ahead of a cost-effectiveness appraisal by UK's NICE, AstraZeneca is paying for EGFR mutation testing for non-small cell lung cancer patients to determine if they will benefit from treatment with Iressa. The genetic testing program is part of a patient access scheme the company has agreed to with the National Health Service to provide more granularity about the cost and value of the treatment.
Scientists from Case Western Reserve University and Fluidigm have demonstrated how the nanofluidic digital PCR platform can detect and quantify EGFR mutations at the single-molecule level from lung tumors, including FFPE samples.
GSK is conducting a Phase III study for a MAGE-A3-targeting therapeutic for the adjuvant treatment of melanoma. To receive the drug in the study, participants' tumors must be shown to express MAGE-A3 via a molecular test that Abbott is developing.
Clarient Insight Dx Pulmotype is a five-antibody immunohistochemistry test that the company said can be used to aid in the histological distinction between adenocarcinoma and squamous cell carcinoma in NSCLC tumor specimens.
Using gene expression data on nearly 800 non-small lung cancer samples from four previously published studies, a team of Duke University researchers has identified age- and sex-specific pathways linked to NSCLC recurrence risk.